Telix Pharmaceuticals Limited

ASX TLX.AX

Telix Pharmaceuticals Limited Return on Assets (ROA) for the year ending December 31, 2023: 1.31%

Telix Pharmaceuticals Limited Return on Assets (ROA) is 1.31% for the year ending December 31, 2023, a 103.28% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Telix Pharmaceuticals Limited Return on Assets (ROA) for the year ending December 31, 2022 was -39.94%, a 45.52% change year over year.
Telix Pharmaceuticals Limited Return on Assets (ROA) for the year ending December 31, 2021 was -73.32%, a -168.59% change year over year.
Telix Pharmaceuticals Limited Return on Assets (ROA) for the year ending December 31, 2020 was -27.30%, a -0.51% change year over year.
Telix Pharmaceuticals Limited Return on Assets (ROA) for the year ending December 31, 2019 was -27.16%, a -50.64% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

ASX: TLX.AX

Telix Pharmaceuticals Limited

CEO	Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA
IPO Date	Nov. 14, 2017
Location	Australia
Headquarters	55 Flemington Road
Employees	415
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Medical Instruments Pharmaceuticals

Description

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Key trends

Past 5 years